Effect of aspirin on the action of bucolome on uric acid excretion

概要

論文の詳細を見る
5-n-Butyl-1-cyclohexy1-2,4,6-trioxo-perhydropyrimidine, or bucolome (BCP) has been found to cause uric acid excretion. Aspirin ( ASA ) is also known to affect uric acid excretion by the kidneys. In the present study, we evaluated the effect of ASA on serum uric acid level and urinary uric acid excretion, both of which are enhanced by BCP. Subjects were 24 healthy males, who were divided into three groups on the basis of drug administration, as follows: Group 1.: single oral administration of 600 mg of BCP only Group 2.: simultaneous administration of 600 mg of BCP and 990 mg of ASA Group 3.: administration of 2,970 mg of ASA, followed by 600 mg of BCP and 990 mg of ASA on the next day Group 1 showed a significant reduction in serum uric acid level and an increase in urinary uric acid excretion - hours after administration. The rise in urinary uric acid excretion coincided with the peak in the serum BCP concentration. In Group 2, BCP concentration showed a tendency to decrease, while the reduction in serum uric acid level-hours after administration and increase in urinary uric acid excretion - hours after administration were found to be less prominent than in Group 1. In Group 3, the serum ASA level showed a peak of 98.4±19.8μg/ml within one hour, while the blood level of BCP at that time was significantly reduced. In addition, a transient increase in uric acid excretion at 0 to 2 hours after administration was noted, suggesting dysfunction of uric acid reabsorption associated with ASA. Subsequently, urinary uric acid excretion peaked at 4 to 6 hours after administration. The peak was suspected to be due to the action of BCP, although the rise was insignificant. Serum uric acid level remained unchanged.
Japanese Society of Gout and Nucleic Acid Metabolismの論文

Effect of aspirin on the action of bucolome on uric acid excretion

スポンサーリンク

概要

著者

関連論文

スポンサーリンク